Ovarian Hyperstimulation Syndrome
Women's Health
3
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
2
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
M&
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Merck & Co.hCG
Merck & Co.Triptorelin 0.2 mg
Ferring PharmaceuticalsNorprolac
Clinical Trials (3)
Total enrollment: 277 patients across 3 trials
Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS
Start: Mar 2013Est. completion: Oct 201689 patients
Phase 4Completed
Can GnRH Agonist Trigger Prevent Ovarian Hyperstimulation Syndrome?
Start: Nov 2012Est. completion: Jan 20146 patients
Phase 4Terminated
Study Assessing the Effect of 3-week Treatment With One of Three Oral Doses of Quinagolide
Start: Jun 2006Est. completion: May 2008182 patients
Phase 2Completed
Related Jobs in Women's Health
Senior Medical Science Liaison
Ferring Pharmaceuticals
Bangkok, Thailand
20h ago
Senior Key Account Manager
Ferring Pharmaceuticals
Bucureşti, Romania
1w ago
Territory Representative - Miami
Caldera Medical
Miami, FL, US
1w ago
Sales Representative Gynecological Health
Medtronic
Malaga, Andalucia, Spain
1w ago
Sales Representative, Women's Health - Charleston, SC
Viatris (2)
Remote
1w ago
$72K - $108K/yr
Sales Representative, Women's Health- Charlotte, NC
Viatris (2)
Remote
1w ago
$72K - $108K/yr
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space